Login to Your Account

Regulatory NEWS
The Supreme Court swept away a hurdle Monday that kept drugmakers and other defendants from moving class action suits to federal courts under the Class Action Fairness Act (CAFA).

As the year winds to a close, it's out with the not-so-old and in with the new at the U.S. Patent and Trademark Office, as it issues a new interim guidance to help its examiners determine §101 subject matter eligibility.

The EMA has endorsed adaptive licensing, in which therapies are given early approval in a restricted patient population based on small clinical studies.

More Regulatory Headlines

Cast Your Vote

Has biotech’s bubble burst?: